Focus: Forest Devices is a biotech company developing a portable EEG-based device with machine learning for rapid diagnosis of stroke subtypes, particularly large vessel occlusions. The company operates in neurology and cardiovascular markets from Pittsburgh, PA.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Forest Devices to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Forest Devices's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
SSRI generic generating 73% of company revenue; multiple ANDA approvals suggest commodity product with limited differentiation.
Help build intelligence for Forest Devices
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Original branded SSRI nearing loss of exclusivity; $3M revenue trajectory suggests erosion accelerating.
Combination analgesic in pre-launch phase; minimal revenue impact to date.
Legacy bronchodilator with negligible revenue; obsolete in modern asthma/COPD therapy.
Opioid-NSAID combination nearing exclusivity loss; reputational risk in current opioid climate.
Sympathomimetic amine weight-loss agent; obsolete in era of GLP-1 agonists.
Generic phendimetrazine; duplicate entry with minimal market traction.
Another phendimetrazine formulation; redundant portfolio with no competitive differentiation.
Fourth phendimetrazine brand; suggests legacy generic portfolio optimization rather than innovation.
99 discontinued, 8 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub